TrialJAMA oncology2016

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

Guo Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.